Skip to main content
Signal8

NovAccess Global Inc. (XSNX)

Operating as a biopharmaceutical firm, NovAccess Global Inc. focuses on developing innovative immunotherapies to treat individuals with brain tumors across the United States. Their primary expertise is in pioneering research that leverages a patient's own immune system to target and eliminate cancerous cells. The company, founded in 1997, has its headquarters situated in Chesterland, Ohio.

Sector: Biotechnology

Industry: Biotechnology

NovAccess Global Inc. logo

NovAccess Global Inc.

OTC:XSNXHealthcare
$0.0001
CLOSED
Mkt Cap$6K
EV-
Float26.32M
O/S61.65M
VOL200 sh
$ Vol$0
RVOL1.00×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
NovAccess Global Inc. logoOTC:XSNXClosed$0.0001